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Accumulation of unfolded proteins in the endoplasmic reticulum (ER) activates homeostatic responses collectively termed
the unfolded protein response. Among the three principal signaling pathways operating in mammals, activating tran-
scription factor (ATF)6 plays a pivotal role in transcriptional induction of ER-localized molecular chaperones and
folding enzymes as well as components of ER-associated degradation, and thereby mouse embryonic fibroblasts deficient
in ATF6 are sensitive to ER stress. However, ATF6-knockout mice show no apparent phenotype under normal growing
conditions. In this report, we burdened mice with intraperitoneal injection of the ER stress-inducing reagent tunicamycin
and found that wild-type mice were able to recover from the insult, whereas ATF6-knockout mice exhibited liver
dysfunction and steatosis. Thus, ATF6-knockout mice accumulated neutral lipids in the liver such as triacylglycerol and
cholesterol, which was ascribable to blockage of -oxidation of fatty acids caused by decreased mRNA levels of the
enzymes involved in the process, suppression of very-low-density lipoprotein formation due to destabilized apolipopro-
tein B-100, and stimulation of lipid droplet formation resulting from transcriptional induction of adipose differentiation-
related protein. Accordingly, the hepatocytes of tunicamycin-injected knockout mice were filled with many lipid droplets.
These results establish links among ER stress, lipid metabolism, and steatosis.
INTRODUCTION
Proteins must be properly folded to exert their respective
functions assigned by genetic code. Newly synthesized se-
cretory and transmembrane proteins gain tertiary and qua-
ternary structures in the endoplasmic reticulum (ER), and
only correctly folded proteins are transported to their final
destinations. The quality of these proteins is tightly moni-
tored by a system called ER quality control, which consists
of two different mechanisms (Bukau et al., 2006). Proteins are
folded with the assistance of a number of ER-localized mo-
lecular chaperones and folding enzymes (collectively termed
ER chaperones hereafter). This mechanism is termed the
productive folding mechanism and allows a majority of
newly synthesized proteins to attain native conformations
under normal conditions (Vabulas and Hartl, 2005). In con-
trast, proteins that are incompletely folded or misfolded,
even after chaperone assistance, are retrotranslocated back
to the cytosol to be degraded by the proteasome in a ubiq-
uitin-dependent manner. This mechanism is termed ER-
associated degradation (ERAD) and minimizes the amount
of unfolded or misfolded proteins in the ER (Wilhovsky et
al., 2000; Tsai et al., 2002).
Under a variety of conditions collectively termed ER
stress, however, unfolded proteins are accumulated in the
ER, which is detrimental to the cell. Eukaryotic cells from
yeast to humans activate the unfolded protein response
(UPR) to cope with ER stress (Mori, 2000; Schroder and
Kaufman, 2005; Ron and Walter, 2007). In yeast cells, the
UPR consists of transcriptional control only and is mediated
by Ire1p, a transmembrane protein in the ER, whereas in
metazoan cells it consists of translational and transcriptional
control and is mediated by three ubiquitously expressed
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transmembrane proteins in the ER, namely, IRE1, PERK, and
activating transcription factor (ATF)6. The major targets of
transcriptional control conserved from yeast to humans are
ER chaperones and ERAD components, induction of which
leads to maintenance of the homeostasis of the ER. It has
been shown that transcriptional induction of these ER qual-
ity control proteins is achieved with the Ire1p or Ire-1 path-
way in Saccharomyces cerevisiae (Travers et al., 2000), Caeno-
rhabditis elegans (Shen et al., 2005), and Drosophila
melanogaster (Hollien and Weissman, 2006). In contrast, our
lab and Kaufman’s lab have shown that the ATF6 pathway
is required for transcriptional induction of these ER quality
control proteins in mouse embryonic fibroblasts (MEFs) (Wu
et al., 2007; Yamamoto et al., 2007), thus revealing a switch in
principal regulator from IRE1 to ATF6 during evolution.
ATF6 is not encoded by the yeast genome but is present as
a single gene product in worm and fly cells. In contrast,
ATF6 consists of the two closely related ATF6 and ATF6
in mammalian cells. Both ATF6 and ATF6 are ER mem-
brane-bound transcription factors activated via ER stress-
induced regulated intramembrane proteolysis (Haze et al.,
1999, 2001; Ye et al., 2000). They are synthesized as type II
transmembrane proteins in the ER, designated pATF6(P)
and pATF6(P). On ER stress, these precursor forms relocate
to the Golgi apparatus via COP II vesicles, where they are
cleaved by sequential action of site-1 and site-2 proteases
(Shen et al., 2002; Okada et al., 2003; Nadanaka et al., 2004).
The ATF6/ N-terminal fragments released from the mem-
brane, designated pATF6(N) and pATF6(N), enter the
nucleus and activate transcription of their target genes, be-
cause they contain all domains necessary for an active tran-
scription factor (Yoshida et al., 2000; Yoshida et al., 2001).
Ectopic expression of pATF6(N) results in transcriptional
induction of various ER chaperone genes (Okada et al., 2002).
ATF6 and ATF6 genes have been knocked out in mice
(Wu et al., 2007; Yamamoto et al., 2007). Analysis of MEFs
revealed that ATF6 is the main mediator of transcriptional
induction of ER chaperones and that ATF6 heterodimerizes
with XBP1, the downstream transcription factor of the IRE1
pathway, to mediate transcriptional induction of ERAD
components. Based on the results of microarray analyses,
which were subsequently confirmed by Northern blot hy-
bridization and functional analysis, ATF6 is considered to
be a transcription factor that is specialized in the control of
ER quality control proteins (Adachi et al., 2008). Accord-
ingly, MEFs deficient in ATF6 are sensitive to ER stress. In
contrast, deletion of the ATF6 gene has almost no effect on
the induction of ER quality control proteins. Nonetheless,
ATF6 probably has overlapping functions with ATF6 and
contributes to the UPR, because double knockout of ATF6
and ATF6 genes causes embryonic lethality even though
mice lacking either ATF6 or ATF6 alone seem normal
(Yamamoto et al., 2007).
Here, to define the role of ATF6-mediated regulation of
ER quality control proteins in vivo, we subjected ATF6
/ and / mice to pharmacological ER stress. This was
found to cause liver steatosis. During the preparation of this
article, Kaufman and coworkers conducted similar and ex-
tensive experiments and obtained similar conclusions (Rut-
kowski et al., 2008). However, we obtained results that con-
nect the deficiency in ATF6-mediated regulation of ER
quality control proteins to liver steatosis more directly;
namely, the level of apolipoprotein B-100 (apoB-100), a ma-
jor protein component of very-low-density lipoprotein
(VLDL), was markedly affected by the presence or absence
of ATF6.
MATERIALS AND METHODS
Production of ATF6/, ATF6/, ATF6/, and
ATF6/ Mice and Preparation of Tunicamycin and
Lipopolysaccharide (LPS) Solutions
ATF6 or ATF6 gene was disrupted in the embryonic stem cell line J1 and
male chimeras thereby obtained were crossed with C57BL/6J females to
generate heterozygotes as described previously (Yamamoto et al., 2007). Male
heterozygotes were backcrossed to C57BL/6J females five times for use in the
experiments shown in Figures 1B, 2, 3A, and 6A, and more than seven times
for use in the rest of the experiments, before the production of ATF6/,
ATF6/, ATF6/, and ATF6/ mice. Genotyping was conducted
by polymerase chain reaction (PCR) as described previously (Yamamoto et al.,
2007). Mice were housed in a temperature-controlled room with a 12-h
light/dark cycle and had free access to normal chow diet. Tunicamycin and
LPS were dissolved in 150 mM sucrose and phosphate-buffered saline (PBS),
respectively. Livers taken from mice before or after injection were immedi-
ately frozen in liquid nitrogen, unless otherwise indicated.
Histological Analysis
Unfrozen livers were fixed in 4% paraformaldehyde in PBS, embedded in
paraffin, sectioned to 5 m in thickness, and stained with hematoxylin and
eosin. To visualize neutral lipids, frozen liver sections (10 m in thickness)
were stained with oil red o according to the standard procedure. Apoptosis
was detected by terminal deoxynucleotidyltransferase-mediated dUTP nick
end labeling (TUNEL) assay by using an In Situ Cell Death Detection kit,
alkaline phosphatase (Roche Diagnostics, Basel, Switzerland) according to the
manufacturer’s instructions. For electron micrographic analysis, mice were
perfused with 0.1 M cacodylate buffer, pH 7.4, containing 2% paraformalde-
hyde and 2.5% glutaraldehyde. Livers were dissected and further fixed for 2 h
at room temperature. Sections were processed as described previously
(Harada et al., 1990) and examined with an electron microscope (model 1010;
JEOL, Tokyo, Japan) at 100 kV.
Biochemical Determinations
Serum alanine aminotransferase and total protein levels were measured with
blood samples obtained from a tail vein by using VetScan (Abaxis, Union
City, CA). Total lipids were extracted from 30 mg of frozen liver according
to a previously published method (Bligh and Dyer, 1959). Hepatic triacylglyc-
erol (triglyceride) and cholesterol levels as well as those in plasma were
measured using a Triglyceride Test kit (Wako Pure Chemicals, Osaka, Japan)
and LabAssay Cholesterol kit (Wako Pure Chemicals), respectively.
Immunoblotting
Total liver lysates were prepared by homogenizing frozen liver with a Teflon
pestle in 10 volumes of 80 mM Tris-HCl buffer, pH 6.8, containing 2% SDS, 50
M MG132, and protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan),
followed by boiling, sonication, and clarification by centrifugation. Liver
microsomes were prepared according to the published procedure (Uchiyama
et al., 2006). In brief, frozen liver was homogenized with a Teflon pestle in 10
volumes of 20 mM Tris-HCl buffer, pH 7.5, containing 0.25 M sucrose, 50 M
MG132, and protease inhibitor cocktail. Homogenates were centrifuged at
8000  g for 10 min, and the resulting supernatant was further centrifuged at
134,000  g for 1 h. Microsomal pellets were suspended in the homogenizing
buffer. Protein content was determined using a BCA Protein Assay kit (Pierce
Chemical, Rockford, IL). These samples were analyzed by standard proce-
dures (Sambrook et al., 1989) using Western Blotting Luminol Reagent ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). Chemiluminescence
was visualized using an LAS-3000 LuminoImage analyzer (Fujifilm, Tokyo
Japan). Anti-ATF6 antibody was as described previously (Haze et al., 2001).
Anti-KDEL (anti-BiP), anti-GRP94, anti-ERp72, anti-protein disulfide isomer-
ase (PDI), and anti-HSP47 antibodies were purchased from Stressgen (Ann
Arbor, MI). Anti-CHOP (anti-GADD153) and anti-apoB-100 antibodies were
obtained from Santa Cruz Biotechnology. Anti-actin and anti-adipose differ-
entiation-related protein (ADRP) antibodies were from Millipore (Billerica,
MA) and Progen (Heidelberg, Germany), respectively.
Microarray Analysis and Northern Blot Hybridization
Total RNA was extracted from frozen livers by using an RNeasy mini kit
(QIAGEN, Venlo, The Netherlands). Microarray analysis was performed es-
sentially as described previously (Adachi et al., 2008). Total RNA extracted
from livers of mice 48 h after intraperitoneal injection of vehicle (150 mM
sucrose) alone, or tunicamycin was converted to cDNA, which was then
labeled with cyanine 3-cytidine 5-triphosphate (CTP) or cyanine 5-CTP,
respectively. These labeled cRNA probes were mixed and hybridized with a
4  44K Agilent oligo microarray (Whole Mouse Genome; Agilent Technol-
ogies, Santa Clara, CA).
Northern blot hybridization was performed according to standard proce-
dures published previously (Sambrook et al., 1989). Digoxigenin-labeled
cDNA probes were prepared using PCR according to the manufacturer’s
K. Yamamoto et al.
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instructions (Roche Diagnostics) and hybridized with RNA electrophoresed
and blotted on a membrane. Subsequent reaction with anti-digoxigenin anti-
body (Roche Diagnostics) and treatment with the chemiluminescent detection
reagent CDP-star (GE Healthcare, Chalfont St. Giles, United Kingdom) were
performed according to the manufacturers’ specifications. Chemilumines-
cence was visualized using an LAS-3000 LuminoImage analyzer (Fujifilm).
Sucrose Gradient Centrifugation to Separate Lipid
Droplets (LDs)
LDs were separated by sucrose gradient centrifugation according to a previ-
ously published procedure (Pol et al., 2004). Approximately 50 mg of frozen
liver was homogenized with a Teflon pestle in 10 volumes of 20 mM Tris-HCl
buffer, pH 7.5, containing 8% sucrose, 50 M MG132, and protease inhibitor
cocktail, and then the homogenate was centrifuged at 1000 g for 10 min. The
resulting supernatant was mixed with an equal volume of 20 mM Tris-HCl
buffer, pH 7.5, containing 70% sucrose. This mixture (350 l; 39% sucrose) was
placed at the bottom of a centrifugation tube onto which 350 l each of 20 mM
Tris-HCl buffer, pH 7.5, containing 20, 10, and 5% sucrose was layered in a
stepwise manner. The loaded tubes were centrifuged at 50,000 rpm (120,000–
214,000  g) for 3 h at 4°C.
Cell Culture and Transfection
Human embryonic kidney (HEK)293T and HepG2 cells were cultured in
DMEM (glucose at 4.5 g/l) supplemented with 10% fetal bovine serum, 2 mM
glutamine, and antibiotics (100 U/ml penicillin and 100 g/ml streptomycin)
at 37°C in a humidified 5% CO2, 95% air atmosphere. Transfection was carried
out using MicroPorator MP-100 (Digital Bio, Seoul, Korea) according to the
manufacturer’s instructions. pcDNA-ATF6(171-373) to express a dominant-
negative form of ATF6 was constructed previously (Haze et al., 1999).
RESULTS
Induction of Liver Dysfunction in ATF6 / Mice after
Tunicamycin Injection
We injected tunicamycin intraperitoneally into ATF6 /
and / male mice (8–10 wk) at a dose of 1 g/g body
weight, which was previously used in analyses of CHOP and
caspase-12 knockout mice (Zinszner et al., 1998; Nakagawa et
al., 2000). Tunicamycin causes ER stress by inhibiting protein
N-glycosylation (Kaufman, 1999). Results showed that both
types of mice lost weight immediately after tunicamycin
injection (Figure 1A, left). After a continuous decrease for
4 d, the body weight of ATF6 /mice started to increase
from day 5, indicating recovery from the tunicamycin insult.
In marked contrast, all ATF6 / mice died at day 3, dem-
onstrating that tunicamycin injection conferred fatal damage to
ATF6 / mice. Importantly, ATF6 / and / mice
showed no significant difference in changes in body weight
after injection of LPS, an endotoxin derived from Gram-nega-
tive bacterial outer membrane that is known to cause inflam-
mation (Trent et al., 2006) (Figure 1A, right). It should be noted
that our results are consistent with those previously published
by Kaufman et al. (Wu et al., 2007; Rutkowski et al., 2008),
although ATF6 / mice died much earlier in our experi-
ments than in their experiments, despite the injection of the
same amount of tunicamycin.
Dissection of the abdomen revealed that the liver of ATF6
/ but not ATF6 / mice turned pale at 48 h after
tunicamycin injection (Figure 1B). No such marked difference
was observed when ATF6 / and / mice were chal-
lenged with LPS or when tunicamycin was injected into ATF6
/ or / mice (Figure 1B). Histological analysis using
hematoxylin and eosin staining confirmed a marked difference
between the liver of ATF6 / and / mice, particularly
at 48 h after tunicamycin injection (Figure 2A). Accordingly,
the level of alanine aminotransferase (ALT), an index of hepa-
tocyte injury, was increased more than twofold in the serum of
ATF6 / mice compared with that of ATF6 / mice,
whereas the level of total protein, an index of liver function, as
well as albumin was decreased, all three from 48 h after tuni-
camycin injection (Figure 2B and Supplemental Figure 1). We
observed no significant difference in the morphology of the
kidney or other organs between ATF6 / and / mice
after tunicamycin injection (our unpublished observation).
These results indicate that tunicamycin-induced injury of the
liver is specific to ATF6 / mice.
Immunoblotting analysis of liver lysates showed that the
induction of four major ER chaperones, namely, BiP, GRP94,
ERp72, and PDI, observed in tunicamycin-injected ATF6
/mice was indeed lost or greatly mitigated in ATF6/
mice (Figure 2C), as expected from the results obtained with
Figure 1. Effect of tunicamycin injection on
body weight and liver appearance of ATF6
/ and / mice. (A) Tunicamycin (Tm) or
LPS was intraperitoneally injected into ATF6
/ and / mice each at a dose of 1 or 5
g/g body weight, respectively. Body weights
of injected mice were determined daily for 7 d
and are presented after normalization to that at
day 0 of injection as the means  SEM (n  4
for Tm-injected ATF6/mice and n 5 for
others). All ATF6 / mice injected with
tunicamycin died at day 3. (B) Tm or LPS was
injected into ATF6 / and / mice as
well as ATF6 / mice as described in A.
The abdomen of injected mice was dissected
and photographed after 48 h.
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MEFs (Yamamoto et al., 2007). The liver damage in ATF6
/mice could be explained, at least in part, by tunicamycin-
induced apoptosis of hepatocytes; TUNEL-positive cells were
significantly increased in the liver of ATF6/mice as early
as 12 h after tunicamycin injection compared with ATF6/
mice (Figure 2D). This apoptosis may be independent of
CHOP, which is implicated in ER stress-induced cell death
(Zinszner et al., 1998), because CHOP was induced at the
protein level in the liver of both ATF6/ and/mice at
12 h after tunicamycin injection (Figure 2C). Regardless, these
results suggest the importance of ATF6-mediated upregula-
tion of the levels of ER quality control proteins in protecting the
mouse liver from ER stress-induced damage.
Induction of Liver Steatosis in ATF6 / Mice after
Tunicamycin Injection
Consistent with the discolored appearance of the liver (Figure
1B), we found that the liver of ATF6 /mice injected with
tunicamycin was much more positive to oil red O staining than
that of ATF6 / mice (Figure 3A). Indeed, the level of
triacylglycerol (triglyceride) in the liver of ATF6 / mice
was markedly increased compared with that of ATF6 /
mice 48 h after tunicamycin injection (Figure 3B). Furthermore,
the level of total cholesterol in the liver of ATF6 / mice
was significantly increased compared with that of ATF6/
mice at this time (Figure 3C). In contrast, levels of triacylglyc-
erol and total cholesterol in the plasma decreased similarly in
both ATF6 / and / mice after tunicamycin injection
(Figure 3, D and E). Thus, tunicamycin injection caused the
specific accumulation of neutral lipids in the liver of ATF6
/ mice, leading to liver steatosis.
Triacylglycerol is synthesized mainly in liver via three
cycles acylation of glycerol-3-phosphate by using acyl-CoA,
which is produced through the activation of fatty acids
(Figure 3F). Fatty acid levels in the liver are regulated by the
balance between uptake, synthesis, catabolism (-oxidation),
and export (Bradbury, 2006; Reddy and Rao, 2006; Duval et
al., 2007). To determine which of theses processes was af-
fected by tunicamycin injection, we performed microarray
analysis by using RNA independently prepared three times
from liver of ATF6 / and / mice 48 h after the
injection of tunicamycin or vehicle (150 mM sucrose) alone.
Fluorescent intensities obtained with 9656 of 41,534 genes
mounted on slides were at least twofold higher than back-
ground intensities in all 12 determinations (3 each of vehicle
and tunicamycin injection in ATF6 / and / mice).
Figure 2. Effect of tunicamycin injection on liver func-
tion of ATF6 / and / mice. (A) Tunicamycin
(Tm) was injected into ATF6 / and / mice as
described in Figure 1A. Liver tissue sections were pre-
pared at the indicated time points after injection and
stained with hematoxylin and eosin. Bar, 100 m (a–h)
and 50 m (i and j). (B) Tm was injected into ATF6
/ and/mice as described in Figure 1A. Levels of
ALT and total protein in the serum of injected mice were
determined at the indicated time points and are pre-
sented as the means  SEM (n  3). *p  0.05. (C) Tm
was injected into ATF6 / and / mice as de-
scribed in Figure 1A. Liver lysates were prepared at the
indicated time points after injection and analyzed by
immunoblotting using antibody to BiP, GRP94, ERp72,
CHOP, PDI, ADRP, or actin. (D) Tm was injected into
ATF6 / and / mice as described in Figure 1A.
TUNEL-positive cells were determined in liver tissue
sections prepared 12 h after injection and are presented
as the means  SEM (n  3). *p  0.05. (E) HEK293T
cells were untreated () or treated for 12 h with 2
g/ml Tm, 300 nM thapsigargin (Tg), or 2 mM dithio-
threitol (DTT). The cell lysates were prepared and ana-
lyzed by immunoblotting using antibody to ADRP, BiP,
or actin.
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As shown in Table 1, genes involved in fatty acid metabo-
lism were generally down-regulated in ATF6 / mice,
probably due to tunicamycin-induced liver dysfunction (see
ratio [%] that is change in knockout [KO] divided by change
in wild type [WT]). We first checked genes involved in the
uptake of fatty acids, namely, the plasma membrane fatty
acid binding protein (FABPpm)/mitochondrial aspartate
amino transferase (AST), fatty acid translocase/CD36, and
fatty acid transport protein (FATP)/solute carrier family 27
a1 (Slc27a1) genes (Bradbury, 2006; Duval et al., 2007). As
shown in Table 1, expression levels of these genes were
unchanged or lower in the liver of ATF6 /mice than in
that of ATF6 / mice 48 h after tunicamycin injection,
suggesting that fatty acid uptake was not a key event in the
accumulation of triacylglycerol in ATF6 / mice.
We next checked genes involved in the synthesis of fatty
acids. De novo synthesis of fatty acids is regulated by three
transcription factors, namely, sterol regulatory element-
binding protein (SREBP)-1, carbohydrate response element-
binding protein (ChREBP), and peroxisome proliferator-ac-
tivated receptor (PPAR) (Reddy and Rao, 2006). Fatty acid
synthase and stearoyl-CoA desaturase are targets of
SREBP-1. Microarray and Northern blot hybridization anal-
yses showed that the level of SREBP-1 mRNA was severely
decreased in the liver of both ATF6 / and / mice
after tunicamycin injection (Table 1 and Figure 4A). The
level of ChREBP mRNA also was decreased in the liver of
ATF6 / mice after tunicamycin injection. Although
both microarray and Northern blot hybridization showed an
increase in the level of PPAR mRNA in the liver of ATF6
/ compared with ATF6 / mice at 12 and 48 h after
tunicamycin injection (Table 1 and Figure 4A), this enhance-
ment effect might be canceled by a marked decrease in the
level of SREBP-1 mRNA. These results suggest that the
synthesis of fatty acids is generally suppressed after tunica-
mycin injection regardless of genotype.
Fatty acids are catabolized to acetyl-CoA for use in energy
production mainly by -oxidization in mitochondria and
peroxisomes (Figure 3F). Carnitine palmitoyl transferases
(CPTs)-I and -II and acyl-CoA oxidase (Acox1) are key en-
zymes in mitochondrial and peroxisomal -oxidization, re-
spectively. PPAR is a master transcriptional regulator of
genes involved in -oxidization in mitochondria and peroxi-
somes (Reddy and Rao, 2006; Duval et al., 2007). Expressed
mRNA levels of these proteins in liver of ATF6 / mice
were significantly lower than those in ATF6/mice 48 h
Figure 3. Effect of tunicamycin injection on lipid
contents in the liver of ATF6 / and / mice.
(A) Tunicamycin (Tm) was injected into ATF6/
and / mice as described in Figure 1A. Liver
tissue sections were prepared at the indicated time
points after injection and stained with oil red O. Bar,
50 m. (B) Tm was injected into ATF6 / and
/ mice as described in Figure 1A. Levels of tri-
acylglycerol (triglyceride) in the liver were deter-
mined at the indicated time points after injection and
are presented as the means SEM (n 3). *p 0.05.
(C) Tm was injected into ATF6/ and/mice
as described in Figure 1A. Levels of total cholesterol
in the liver were determined at the indicated time
points after injection and are presented as the
means SEM (n 3). *p 0.05. (D) Tm was injected
into ATF6 / and / mice as in Figure 1A.
Levels of triacylglycerol (triglyceride) in plasma
were determined at the indicated time points after
injection and are presented as the means SEM (n
4). *p  0.05. (E) Tm was injected into ATF6 /
and / mice as described in Figure 1A. Levels of
total cholesterol in plasma were determined at the
indicated time points after injection and are pre-
sented as the means  SEM (n  4). *p  0.05. (F)
Schematic presentation of metabolism of fatty acids
and cholesterol.
ER Quality Control and Lipid Droplet Formation
Vol. 21, September 1, 2010 2979
after tunicamycin injection when determined by microarray
(Table 1). These observations were confirmed by Northern
blot hybridization (Figure 4B). PPAR mRNA and CPT-II
mRNA levels were decreased at 12 h after tunicamycin
injection in ATF6 / and / mice and then recovered
at 48 h after tunicamycin injection in ATF6 / but not in
ATF6 / mice. The level of Acox1 mRNA in ATF6
/ mice was significantly lower than that in ATF6 /
mice 48 h after tunicamycin injection. These results suggest
that a sustained decrease in the catabolism of fatty acids in
the liver of ATF6 / mice contributes to the accumula-
tion of triacylglycerol in response to tunicamycin injection.
Sustained Decrease in apoB-100 in ATF6 / Mice after
Tunicamycin Injection
Amounts of triacylglycerol and cholesterol excess to those
required by the liver are incorporated into VLDL particles
and secreted into the plasma (Figure 3F). Two proteins are
essential to the formation of VLDL. apoB-100 is a major
protein component of VLDL, which is present on the surface
of VLDL, whereas microsomal triglyceride transfer protein
(MTP), a luminal ER protein, mediates the assembly of
apoB-100 with neutral lipids. We therefore checked the
mRNA levels of these proteins in the microarray analysis
data. The level of MTP mRNA in the liver of tunicamycin-
injected ATF6 / mice was lower than that in similarly
treated ATF6/mice (Table 1), which was confirmed by
Northern blot hybridization analysis of mRNA prepared
from livers at 48 h after tunicamycin injection (Figure 4C).
PDI is an essential component of the microsomal triglyceride
transfer enzyme (Noiva, 1999). We found that the protein
level of PDI was lower in the liver of tunicamycin-injected
ATF6 / mice than in similarly treated ATF6 /
mice (Figure 2C). These observations suggested that the
Table 1. Determination of expression levels of genes involved in lipid metabolism in tunicamycin- or vehicle-injected ATF6 / and /
mice by microarray analysisa
Gene name
Basal (%)
KO vehicle
WT vehicle
Change in WT (%)
Tm
Vehicle
Change in KO (%)
Tm
Vehicle
Ratio (%)
Change in KO
Change in WT GenBank
FA uptake
FABPm/AST 92 88 7.1 90  6.1 100 NM_010325
Fatty acid translocase/CD36 90 93 31 30  3.7 32 L23108
FATP/Slc27al 75 52 17 32  7.0 62 NM_011977
FA activation
ACSL1 110 61 2.6 7.6  1.6 12 NM_007981
FABP1 170 123 57 0.35  0.17 0.28 NM_017399
FATP2/Slc27a2 120 101 5.2 5.7  2.6 5.6 NM_011978
FATP5/Slc27a5 110 82 32 6.3  1.0 7.7 NM_009512
FA -oxidation
PPAR 50 56  12 14  3.8 25 NM_011144
CPT-Ia 83 101 11 42  4.2 42 NM_013495
CPT-II 110 60 9.3 16  5.6 27 NM_009949
ACOX1 130 215 29 32  10 15 NM_015729
FA synthesis
SREBP-1 64 30 14 6.8  2.9 23 NM_011480
Fatty acid synthase 97 12 2.2 4.4  1.9 37 NM_007988
Stearoyl-CoA desaturase1 70 9.6 2.9 7.8  1.6 81 NM_009127
ChREBP 83 72 23 8.9  3.3 12 NM_021455
PPAR 70 93  11 112  15 120 NM_011146
PPRC1 61 107 24 454  61 420 BC066048
LD formation
ADRP 45 132 44 966  442 730 NM_007408
TIP47 81 89 7.1 450  280 510 NM_025836
FA export
MTP 95 82 2.6 30  9.0 37 NM_008642
Apolipoprotein
Apolipoprotein A-I 73 73 33 3.0  5.9 4.1 NM_009692
Apolipoprotein A-II 193 125 46 6.9  1.9 5.5 NM_013474
Apolipoprotein A-V 300 98 21 3.6  0.40 3.7 NM_080434
Apolipoprotein B 120 122 30 15  8.0 12 AK147540
Apolipoprotein C-I 120 93 18 19  10 20 NM_007469
Apolipoprotein C-II 110 120 29 17  2.2 14 NM_009695
Apolipoprotein C-III 73 38 4.2 6.8  1.1 18 NM_023114
Apolipoprotein E 110 104 15 22  9.4 21 NM_009696
Cholesterol metabolism
SREBP-2 91 41 8.9 11  2.5 27 AK172219
HMG-CoA synthase1 100 22  7.9 13  7.7 59 NM_145942
HMG-CoA synthase2 72 77  16 11  3.7 14 NM_008256
HMG-CoA reductase 86 14 7.3 6.1  1.3 44 AK159899
LDL receptor 75 26 8.1 3.8  6.9 15 BC053041
LRP1 96 72 11 8.8  2.3 12 NM_008512
a Aray analysis was conducted using total RNA independently prepared three times from livers 48 h after intraperitoneal injection of
tunicamycin or vehicle (150 mM sucrose) alone into ATF6 / (WT) and / (KO) mice. Basal (%), change in WT (%), change in KO (%),
and ratio (%) were determined as indicated at the top. Gene accession numbers also are shown.
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microsomal triglyceride transfer activity might be decreased
in the absence of ATF6-mediated transcriptional control.
Given that the levels of SREBP-1 mRNA and ChREBP
mRNA involved in the synthesis of fatty acids were de-
creased after tunicamycin injection (Figure 4A), apoB-100
might not be lipidated in the liver of tunicamycin-injected
ATF6/mice as efficiently as in similarly treated ATF6
/ mice. This leads to degradation of apoB-100 (Oy-
adomari et al., 2006), thereby contributing to lower level of
apoB-100 observed in the liver of tunicamycin-injected
ATF6 / mice than in similarly treated ATF6 /
mice (see below), although the difference in SREBP-1
mRNA, MTP mRNA, and PDI protein levels between
ATF6 / and / mice was not striking.
The level of apoB mRNA in the liver of tunicamycin-
injected ATF6 / mice was severely decreased com-
pared with that in similarly treated ATF6 / mice in
microarray analysis (Table 1). In contrast, Northern blot
analysis showed that apoB mRNA levels in the liver of
tunicamycin-injected ATF6 / and / mice were sim-
ilar at all time points (Figure 4C). Because apoB mRNA is
very long (see below), it could not be adequately hybridized
to short oligonucleotide probes used in microarray analysis,
giving rise to erroneous underestimation. Because apoB-100
consists of 4536 amino acids, and thus represents one of the
biggest proteins in the cell, and contains 25 cysteines and 20
N-linked glycosylation sites (Fisher and Ginsberg, 2002), we
considered that the folding of apoB-100 would be difficult
under ER stress conditions. We therefore examined the effect
of tunicamycin injection on the level of apoB-100 in the liver
of ATF6 / and / mice. As shown in Figure 5A,
levels in uninjected ATF6/ and/mice were similar
(lanes 1, 2, 7, 8, 13, 15, 16, 21, 25, 29, and 33) and were
similarly markedly decreased 12 h after tunicamycin injec-
tion (Figure 5A, lanes 3, 4, 9, 10, 17, 18, 30, and 34). Impor-
tantly, the level of apoB-100 in the liver of ATF6 /mice
was restored at 48 h after tunicamycin injection (Figure 5A,
lanes 5, 6, 14, and 32). In marked contrast, the level of
apoB-100 in the liver of ATF6 / mice remained low at
48 h after tunicamycin injection (Figure 5A, lanes 11, 12, 19,
20, and 36).
To provide an explanation for the above-mentioned ob-
servation and to exclude the unfavorable possibility that
tunicamycin was effective in ATF6 / mice for a longer
time than in ATF6 / mice, we checked the glycosyla-
tion status of proteins in the ER before and after tunicamycin
injection by using pATF6(P), a glycoprotein spanning the
ER membrane once. For this purpose, liver lysates were
digested with or without endoglycosidase H (endo H) and
analyzed by immunoblotting with anti-ATF6 antibody.
The mobility of pATF6(P) differed before and after endo H
treatment (Figure 5B, compare lane 8 with lane 9), indicating
glycosylation of ATF6 with a high mannose-type oligosac-
charide [faster migrating band representing unglycosylated
ATF6 was designated pATF6(P*)]. ATF6 was detected as
glycosylated pATF6(P) in the liver of uninjected ATF6/
and / mice, as expected (Figure 5B, lanes 1 and 5). In
contrast, ATF6 was detected as unglycosylated pATF6(P*)
even without endo H treatment 12 h after tunicamycin injec-
tion in ATF6 / and / mice (Figure 5B, lanes 2 and 6),
indicating that tunicamycin indeed blocked protein N-glyco-
sylation. Analysis of ATF6 showed that ATF6 started to
be glycosylated again from 24 h after tunicamycin injection
(Figure 5B, lanes 3 and 7) and was fully glycosylated after
48 h (Figure 5B, lanes 4 and 8), probably due to the catabo-
lism of tunicamycin. We also checked the glycosylation sta-
tus of HSP47, an ER-resident molecular chaperone specific
to collagen (Nagata, 2003). Results showed that the ungly-
cosylated form of HSP47 (representing newly synthesized
molecules) was produced after tunicamycin injection in the
livers of ATF6 / and / mice (Figure 5B, compare
lane 2 with lane 1 and lane 6 with lane 5) and disappeared
Figure 4. Effect of tunicamycin injection on
expression levels of various genes involved in
fatty acid metabolism in the liver of ATF6
/ and / mice. (A) Tunicamycin (Tm)
was injected into ATF6 / and / mice
as described in Figure 1A. Total RNA was
prepared from livers at the indicated time
points after injection and analyzed by North-
ern blot hybridization by using a digoxigenin-
labeled probe specific to SREBP-1, ChREBP,
or PPAR. (B) Total RNA was prepared and
analyzed as described in A by using a probe
specific to PPAR, CPT-II, or Acox1. (C) Total
RNA was prepared and analyzed as de-
scribed in A by using a probe specific to MTP,
ApoB, or ADRP. (D) Intensities of each band
obtained in A–C were quantified and are pre-
sented as the means  SEM (n  3) after
normalization to the value obtained for unin-
jected ATF6 / mice. *p  0.05.
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from the liver lysate of ATF6/mice no later than it did
from that of ATF6 / mice (Figure 5B, lanes 3, 4, 7, and
8). Thus, analyses of ATF6 and HSP47 revealed no signif-
icant difference in the duration of tunicamycin action in
ATF6 / and / mice.
The above-mentioned results suggested the possibility
that tunicamycin-induced unglycosylation caused misfold-
ing of apoB-100, which was then degraded by the protea-
some, because it was previously shown that apoB-100 was
ubiquitinated and degraded by the proteasome when as-
sembly of apoB-100 with lipids was blocked (Zhou et al.,
1998). apoB-100 levels in the liver of ATF6 / mice were
recovered at 24 h albeit that the extent varied among indi-
viduals (Figure 5A, lanes 22, 23 24, and 31), probably due to
differences in the rate of catabolism of tunicamycin, whereas
apoB-100 levels all remained low in the liver of ATF6 /
mice (Figure 5A, lanes 26, 27, 28, and 35). To test this notion
further, we transfected HepG2 cells with vector alone or
vector expressing a dominant negative form of ATF6 (con-
taining the basic leucine zipper region but lacking the tran-
scriptional activation domain) and determined the stability
of apoB-100 by cycloheximide chase experiments. As shown
in Figure 5C, expression of dominant-negative ATF6 de-
stabilized apoB-100 without affecting the stability of actin,
suggesting that ATF6-mediated transcriptional control is
required for the productive folding of apoB-100. Together,
we considered that apoB-100 in the liver of tunicamycin-
injected mice could be properly folded again when the tu-
nicamycin insult was dismissed only if ER chaperones were
induced by the action of ATF6 but remained misfolded and
degraded if the induction of ER chaperones was compro-
mised due to the absence of ATF6.
Induction of Lipid Droplet Formation in ATF6 / Mice
after Tunicamycin Injection
Among genes involved in fatty acid metabolism, we ob-
served striking differences in the results of microarray anal-
ysis on the two genes; changes in ADRP mRNA and tail-
interacting protein of 47 kDa (TIP47) mRNA levels were 7.3-
and 5.1-fold higher in liver of ATF6 / mice than that of
ATF6 / mice (Table 1). This marked increase in ADRP
mRNA after tunicamycin injection was confirmed by North-
ern blot hybridization (Figure 4C). These mRNA encode two
of several proteins that cover LDs, namely, perilipin, ADRP,
and TIP47, collectively termed PAT proteins (Martin and
Parton, 2006). We found that signals for perilipin obtained in
microarray analysis were too low to be analyzed. Immuno-
blotting analysis also revealed marked induction of ADRP in
the liver of ATF6 / mice but not of ATF6 / mice
after tunicamycin injection (Figure 2C). Interestingly, analy-
Figure 5. Effect of tunicamycin injection on the level of
apoB-100 in the liver of ATF6 / and / mice. (A)
Tunicamycin (Tm) was injected into ATF6 / and
/ mice as described in Figure 1A. Microsomes were
prepared from livers at the indicated time points after
injection. Aliquots (100 g) of microsomal lysates were
analyzed by immunoblotting using anti-apoB-100 anti-
body. The results of four independent experiments are
shown. Bottom right, intensity of each band was quanti-
fied, normalized with the respective value at 0 h, and
plotted against time after tunicamycin injection. (B) Top,
100-g aliquots of microsomal lysates prepared as de-
scribed in A were digested with () or without () endo
H and then analyzed by immunoblotting using anti-
ATF6 antibody. The migration positions of pATF6(P)
and pATF6(P*), the unglycosylated form of pATF6(P),
are indicated. Bottom, 100-g aliquots of microsomal ly-
sates prepared as described in A were analyzed by immu-
noblotting using anti-HSP47 antibody. (C) HepG2 cells
transfected with vector alone (Mock) or vector to express
a dominant-negative form of ATF6 (ATF6DN) were
treated with cycloheximide (CHX) for the indicated pe-
riods. Cell lysates were prepared and analyzed by im-
munoblotting using antibody to ApoB-100 or actin. In-
tensity of each band was quantified, normalized with
the respective value at 0 h, and plotted against time of
cycloheximide treatment. Values are presented as the
mean  SEM (n  3).
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sis of HEK293T cells showed that ADPR was not a target of
the UPR, because it was not induced by any of three ER
stress inducers, namely, tunicamycin, thapsigargin, and di-
thiothreitol (Figure 2E). Because ADRP was induced only
after tunicamycin injection in the liver of ATF6 / mice
(Figure 2C), it is unlikely that ATF6 suppresses the expres-
sion of ADRP constitutively. The mechanism of ADRP in-
duction remains to be determined.
LDs, the site of lipid storage in the cell, contain neutral
lipids such as triacylglycerol and cholesterol ester in their
core, which are surrounded by a monolayer of phospholip-
ids (Tauchi-Sato et al., 2002; Martin and Parton, 2006). We
therefore analyzed liver sections by electron microscopy. As
shown in Figure 6A, hepatocytes of ATF6 / and /
mice before tunicamycin injection were quite similar except
that hepatocytes of / mice contained a few vacuole-like
structures (compare Figure 6A, a and b, vacuoles are indi-
cated by arrows). Interestingly, ribosome-bound rough ER
were markedly enlarged 48 h after tunicamycin injection in
hepatocytes of ATF6 / mice (Figure 6A, c and e [with
higher magnification], rough ER are indicated by arrow-
heads). In marked contrast, the rough ER in hepatocytes of
ATF6 / mice seemed normal, but the hepatocytes in-
stead contained an extremely large number of vacuole-like
structures (Figure 6Ad), which probably represented LDs,
because the structures were completely round and not
surrounded by lipid bilayers (Figure 6Af, with higher
magnification). The presence of ADRP in the structure
was confirmed as follows. Liver taken from ATF6 /
and / mice 0, 12, and 48 h after tunicamycin injection
was homogenized, and the homogenates were separated by
sucrose gradient centrifugation. LDs are known to be recov-
ered in the top fraction; we found that ADRP was indeed
present in the top fraction and that levels were markedly
increased after tunicamycin injection into ATF6 / mice
(Figure 6B). Based on these results, we concluded that tuni-
camycin injection caused liver steatosis by blocking -oxi-
dation of fatty acids, suppressing VLDL formation, and
facilitating LD formation in ATF6 / mice.
DISCUSSION
The liver is a major site for the production of proteins as well
as lipoprotein particles circulating in plasma, and the ER is
a key place for their synthesis and maturation. The protein
Figure 6. Induction of lipid droplet formation in
ATF6 / mice in response to tunicamycin injection.
(A) Tunicamycin (Tm) was injected into ATF6 /
and / mice as described in Figure 1A. Liver tissue
sections were prepared from untreated or tunicamycin-
injected mice after 48 h and analyzed with electron
microscopy. Bar, 10 m (a–d) and 500 nm (e and f). (B)
Tm was injected into ATF6 / and / mice as
described in Figure 1A. Whole liver obtained at the
indicated time points after injection was homogenized
and then subjected to sucrose gradient (5–39% from top
to bottom) centrifugation. An aliquot of 12 collected
fractions was analyzed by immunoblotting using anti-
ADRP antibody.
ER Quality Control and Lipid Droplet Formation
Vol. 21, September 1, 2010 2983
quality control system in the ER is tightly and dynamically
regulated by the UPR, an intracellular signaling from the ER.
Among three ubiquitous signaling pathways operating in
mammalian UPR, namely, the IRE1, PERK, and ATF6
pathways, ATF6 plays a pivotal role in up-regulating var-
ious ER quality control proteins in response to ER stress.
However, ATF6-deficient mice show no apparent pheno-
type under normal growing conditions (Wu et al., 2007;
Yamamoto et al., 2007). In this report, we subjected ATF6-
deficient mice to ER stress pharmacologically and observed
the induction of liver steatosis, which progressed from the
blockage of -oxidation of fatty acids, suppression of VLDL
formation, and facilitation of LD formation.
Kaufman and coworkers conducted similar experiments
with ATF6-deficient mice and found that tunicamycin in-
jection caused liver steatosis, consistent with our results
(Rutkowski et al., 2008). Furthermore, they created mice
harboring liver-specific deletion of IRE1 as well as mice
exhibiting liver-specific blockage of ER stress-induced phos-
phorylation of eukaryotic initiation factor 2, an event im-
mediately downstream of PERK activation. Tunicamycin
injection into these two types of mice also caused fatty liver.
Thus, defects in the three principal UPR signaling pathways
all lead to hepatic steatosis. They found prolonged induction
of the proapoptotic transcription factor CHOP as a conse-
quence of tunicamycin injection into ATF6-deficient mice
and mice harboring liver-specific deletion of IRE1, and
they also found suppression of CCAAT/enhancer-binding
protein (C/EBP) as a consequence of tunicamycin injection
into all three types of mice. They postulated that defective
UPR signaling resulted in sustained ER stress, leading to the
sustained induction of CHOP even during the period in
which the hepatocytes of wild-type mice recovered from the
insult via activation of the UPR. This notion was supported
by formation of fatty liver, prolonged induction of CHOP,
and sustained suppression of C/EBP after tunicamycin
injection into mice deficient in p58IPK, a DnaJ domain-
containing cochaperone of the DnaK protein BiP present in
the ER (Rutkowski et al., 2007). CHOP expression suppresses
C/EBP because CHOP can function as a dominant-nega-
tive regulator of C/EBP family members (Ron and Habener,
1992). This in turn leads to the suppression of metabolic
gene expression through the suppressed expression of their
master regulators, such as SREBP-1 and PPAR, via possible
transcriptional control: it was shown previously that
C/EBP binding sites seem to exist on their promoter re-
gions (Villacorta et al., 2007). Because PPAR is a master
transcriptional regulator of genes involved in -oxidization
in mitochondria and peroxisomes (Reddy and Rao, 2006;
Duval et al., 2007), suppression of its expression contributes
to the accumulation of fatty acids. Our results obtained with
ATF6-deficient mice are generally consistent with those by
Kaufman and coworkers. We indeed observed a more sus-
tained induction of CHOP in ATF6-deficient mice than in
wild-type mice (Figure 2C) as well as suppression of PPAR
expression (Figure 4B).
We sought to correlate the induction of liver steatosis and
LD formation in hepatocytes more directly with the failure
of ATF6-deficient mice to up-regulate ER quality control
proteins in response to ER stress. We therefore checked
expression of apoB-100 at a protein level, which was not
conducted by Kaufman and coworkers. apoB-100, a huge
(4536-amino acid) and heavily-glycosylated (20 potential
sites) protein, is an essential component of VLDL, account-
ing for approximately one third of total lipoproteins present
in VLDL (Fisher and Ginsberg, 2002). Previous results
showed that the half-life of apoB mRNA is quite long (16
h) (Pullinger et al., 1989) but that only 30–60% of newly
synthesized apoB-100 is secreted into the extracellular mi-
lieu (Borchardt and Davis, 1987; Sato et al., 1990), indicating
that the level of apoB-100 is regulated posttranslationally
and that the proper folding of apoB-100 is difficult even
under normal conditions. We suspected that the folding of
apoB-100 is made even more difficult under ER stress con-
ditions. Indeed, we found that apoB-100 levels were greatly
mitigated when protein N-glycosylation in the liver was
blocked by tunicamycin injection, as evidenced from the
analysis of ATF6 and HSP47, regardless of the genotype of
mice (Figure 5A). Importantly, apoB-100 levels were re-
stored in wild-type mice when the effects of tunicamycin
disappeared but remained low in ATF6-deficient mice (Fig-
ure 5A). We cannot formally rule out the possibility that
decreased level of apoB-100 mRNA in tunicamycin-treated
ATF6-deficient mice contributed to sustained decrease in
apoB-100 protein level due to the discrepancy between the
data of microarray analysis (Table 1) and Northern blot
hybridization analysis (Figure 4C). Nonetheless, our results
suggest that the levels of ER quality control proteins can
directly affect the productive folding process of apoB-100.
Resulting down-regulation of apoB-100 favors the accumu-
lation of triacylglycerol and cholesterol, leading to the for-
mation of LDs in hepatocytes and then to the development
of liver steatosis.
Although tunicamycin injection-induced liver steatosis
represents an extreme condition, such that ATF6-deficient
mice die within 3 d after this pharmacological challenge, our
and Kaufman’s results suggest the possibility that chronic
ER stress is involved in the pathogenesis of nonalcoholic
fatty liver disease (NAFLD). NAFLD encompasses a wide
spectrum of liver diseases ranging from simple steatosis,
characterized by the accumulation of triglyceride within
hepatocytes, to nonalcoholic steatohepatitis, which may lead
to liver fibrosis or cirrhosis (Day, 2002; Harrison et al., 2002;
McClain et al., 2004; Adams et al., 2005; Sanal, 2008). The
development of NAFLD is affected by genetic and environ-
mental factors (Day, 2002) and occurs more frequently
among people with diabetes (50%) and obesity (76%) (Ad-
ams et al., 2005). The study of NAFLD in humans is ham-
pered by the genetic heterogeneity within populations, and
no universally applicable noninvasive diagnostic method is
available. Animal models therefore provide valuable tools to
investigation of the pathogenesis of NAFLD (Anstee and
Goldin, 2006). One currently favored hypothesis for the
development of NAFLD is the “two-hit theory” that was
originally proposed for nonalcoholic steatohepatitis (Day
and James, 1998). The first hit increases the vulnerability of
the liver to the second hit through the accumulation of
neutral lipids within hepatocytes (hepatic steatosis), and the
second hit in turn leads to inflammation and hepatocyte
injury (fibrosis or cirrhosis). Several factors have been sug-
gested to play a role in the development of NAFLD, includ-
ing insulin resistance, oxidative stress, mitochondrial dys-
function, dysregulated cytokine metabolism, drugs, toxins,
and abnormal lipid metabolism (Browning and Horton,
2004; Adams et al., 2005; Wei et al., 2008). However, the
mechanisms by which neutral lipids accumulate within
hepatocytes and how steatosis turns into steatohepatitis re-
main elusive.
Interestingly, several recent studies have revealed an un-
expected link between ER stress and liver steatosis or the
involvement of UPR mediators in hepatic lipogenesis or
glycolysis. Homocysteine-induced ER stress caused the ac-
tivation of SREBPs and a subsequent increase in the levels of
triglycerides and cholesterol in the liver (Werstuck et al.,
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2001). Selective deletion in the liver of XBP1, a downstream
transcription factor of IRE1, caused a decrease in lipid
production, leading to severe hypocholesterolemia and hy-
potriglycemia (Lee et al., 2008). Selective blockage in the liver
of ER stress-induced phosphorylation of eukaryotic initia-
tion factor 2, a downstream event of PERK activation,
resulted in a decrease in hepatic glycogen levels and suscep-
tibility to fasting hypoglycemia in lean mice, and enhanced
glucose tolerance and diminished hepatosteatosis in mice
fed a high-fat diet (Oyadomari et al., 2008).
Here, we provide a new linkage between ER stress and
liver steatosis by revealing a new intersection at which the
ATF6 branch of the UPR can directly affect lipid metabo-
lism. In addition to the effects on -oxidation of fatty acids
and the synthesis of LD components, we showed that
ATF6-mediated regulation of ER quality control proteins is
critical to facilitating the folding of apoB-100 and thereby
maintain its level under ER stress conditions, which in turn
minimizes intracellular levels of triglycerides and cholester-
ols in the liver by encapsulating these lipids in VLDL for
secretion into plasma. Together with the results of Kaufman,
our results suggest that chronic ER stress or chronic failure
of ER quality control can act as a first hit in the development
of NAFLD. Chronic ER stress might occur in the liver of
individuals when the function of ER quality control proteins
is compromised or when the homeostatic UPR is not acti-
vated efficiently. By subjecting ATF6-deficient mice to con-
tinuous milder ER stress, we may be able to gain new
insights into the pathogenesis of NAFLD. These studies are
now in progress.
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